Core Insights - The In Vivo CART sector is experiencing rapid development, with four MNC acquisition cases reported in 2025 [1] Group 1: In Vivo CART Technology - In Vivo CART is divided into two technical routes: LNP and lentivirus, both of which have distinct characteristics [1] - The LNP route shows rapid transfection and excellent targeting capabilities in preclinical studies [1] - The lentivirus route, exemplified by Esobiotec's BCMA In Vivo CART, has demonstrated promising early data in a small population of multiple myeloma (MM) patients [1] Group 2: Market Outlook - The overall development of In Vivo CART is progressing swiftly, indicating that future developments in this area warrant close attention [1]

Core Insights - The In Vivo CART sector is experiencing rapid development, with four MNC acquisition cases reported in 2025 [1] Group 1: Technology Routes - In Vivo CART is divided into two technical routes: LNP and lentivirus, both of which have distinct characteristics [1] - The LNP route demonstrates rapid transfection and excellent targeting capabilities in preclinical studies [1] - The lentivirus route, exemplified by Esobiotec's BCMA In Vivo CART, has shown promising early data in a small population of multiple myeloma (MM) patients [1] Group 2: Market Outlook - The overall development of In Vivo CART is progressing swiftly, indicating significant future growth potential [1]